Fisher Releases Perspective on Pharmaceutical Stocks
New research brief from Fisher Investments offers insight to pharmaceutical stocks drivers.

WOODSIDE, CA, September 14, 2011 /24-7PressRelease/ -- Fisher Investments released a new research brief discussing major drivers of pharmaceutical stocks, entitled Two Drivers for Pharmaceutical Stocks. Fisher provides commentary on the global Pharmaceutical industry and the illustrious fears of the "patent cliff."

The piece delves into two drivers affecting Pharmaceutical stocks. The first is upcoming patent expirations and their projected impact on annual sales between 2010 and 2020. The second driver Fisher Investments analyzes is equally important but lesser-known: positive pipeline developments--mainly New Molecular Entity (NME) approvals and their potential to drive up sales and pricing power for Pharmaceutical firms.

In its discussion of what challenges face the Pharmaceutical industry, this new piece explains, "While the patent cliff is a challenge the Pharmaceutical industry must navigate in the coming years, it's important to place it in context with other drivers. This widely publicized concern eases in two years and, balanced against NME approvals, likely isn't as large a negative as many presume, in our view. Weighing these two drivers in the Pharmaceutical industry seems to indicate a brighter outlook than valuations currently reflect."

The full document, which comprehensively explores the previewed topics, can be found at Fisher Investments' website: http://fisherinvestments.bo.lt/pharma.

Press Release Contact Information:

David Eckerly
Fisher Investments
GVP Corporate Communications
13100 Skyline Blvd
Woodside, CA
USA 94062
Voice: 800-851-8845
Fax: 650-350-5290
Website: Visit Our Website